胰高血糖素样肽-1减肥应用的伦理探讨
An Ethical Discussion on the Use of Glucagon-like Peptide-1 for Weight Loss
程欣瑞 1翟晓梅1
作者信息
- 1. 中国医学科学院/北京协和医学院群医学及公共卫生学院 北京 100730
- 折叠
摘要
针对胰高血糖素样肽-1 受体激动剂类药物在治疗肥胖方面的医学价值和潜在滥用的现实情况,深入探讨了该类药物在非糖尿病肥胖治疗中的超适应证应用及其伦理问题,包括医疗资源的合理分配、患者知情同意的重要性以及社会审美标准对医疗决策的影响.并针对上述伦理问题,提出了包括加强药物处方规范、提高公众药物知识、确保患者知情同意等建议.旨在促进胰高血糖素样肽-1受体激动剂类药物在肥胖治疗中的合理及伦理使用,保障医疗伦理和患者安全.
Abstract
This article explores the medical value of glucagon-like peptide-1 receptor agonist analogs and the potential abuse in obesity treatment.It also provides insights into the use of glucagon-like peptide-1 receptor agonist analogs for non-diabetic obesity and discusses related ethical issues.These issues include the equitable allocation of healthcare resources,the importance of patients'informed consent,and the influence of societal aesthetic standards on medical decision-making.Finally,the article makes recommendations to address these issues,including strengthening prescription regulations,improving public awareness of medications,and ensuring patients'informed consent.These recommendations aim to promote the rational and ethical use of glucagon-like peptide-1 receptor agonist analogs in obesity treatment and to safeguard medical ethics and patient safety.
关键词
胰高血糖素样肽-1受体激动剂/超适应证用药/减肥/伦理分析Key words
glucagon-like peptide-1 receptor agonist/off-label drug use/weight loss/ethical analysis引用本文复制引用
出版年
2024
NETL
NSTL
万方数据